RedHill Biopharma reported positive study results concerning its irritable bowel syndrome with diarrhea drug Bekinda, yet investors sent the drugmaker’s stock tumbling.
A study, published in Digestive Diseases and Sciences, analyzed the efficacy of Medial EarlySign’s ColonFlag.
Valeant Pharmaceuticals sold its iNova Pharmaceuticals business to a company jointly owned by Pacific Equity Partners and The Carlyle Group for $930 million.
Landos Biopharma completed a series A financing round raising $10 million.
The FDA approved Bracco Diagnostics’ Tagitol V oral suspension for adult patients undergoing virtual colonoscopy.
More articles on gastroenterology:
GI leader to know: Dr. Steven Desautels of Granite Peaks Gastroenterology
Stock market week-in-review for 5 large GI companies — Sept. 25-29
Drug designations, new devices & more — 15 GI company key notes for September
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
